@article {2444, title = {Cytotoxic Potential of Mitragyna speciosa as Anticancer - A Review}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {December 2024}, pages = {1418-1423}, type = {Review Article}, chapter = {1418}, abstract = {

Background: Herbal treatment has been proposed and researched as an alternative to cancer treatment. One of the reasons contains compounds that have cytotoxic effects. Mitragyna speciosa are known to contain alkaloids and have a cytotoxic effect. Objective: This review aimed to provide information about preclinical studies and investigates the cytotoxicity or anticancer activity of M. speciosa. Methods: Search articles through PubMed, Springer, and Science Direct databases focusing on preclinical trials according to PRISMA guidelines. A database search yielded a total of 206 identifiable studies. Then duplicate removal and feasibility screening were carried out, resulting in 11 studies that were eligible for final analysis. Results: The anticancer potentials reviewed in this study include Neuroblastoma, Leukemia, Colon Cancer, Breast Cancer, Kidney \& Liver Cytotoxicity, Glutathione Transferases Metabolizing Enzymes, Alkaloid Combination of M. speciosa \& Cisplatin, Alkaloid Combination of M. speciosa \& Doxorubicin and Mutagenic-Antimutagenic Activity of M. speciosa. Extracts and dominant alkaloids of M. speciosa have the potential for anticancer neuroblastoma, leukemia, colon, lung and breast cancer. Based on the safety aspect of the mitragynine compound, there is no mutagenic effect on cells. Conclusion: M. speciosa contains the dominant active alkaloid compound, mitragynine. Extracts and alkaloids dominant in M. speciosa have the potential as an anticancer.

}, keywords = {Alkaloids, Cancer, Cytotoxicity, M. speciosa, Mitragynine}, doi = {10.5530/pj.2024.16.228}, author = {Puja Adi Priatna and Retno Widyowati and Sukardiman} } @article {1929, title = {Molecular Docking Estrogen Receptor Alpha Antagonist and P53- MDM2 Inhibitor, ADMET Prediction of Alkaloid Compound from Mitragyna speciosa for Breast Cancer Therapy}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {January 2023}, pages = {912-916}, type = {Original Article }, chapter = {912}, abstract = {

Introduction: Breast cancer is one of the major universal health problems affecting more than two million cases per year. Estrogen receptor alpha (ERα) and P53 are common targets for the treatment of breast cancer and are primarily involved in cell proliferation. The function of p53 protein is regulated by direct binding to MDM2 protein. Therefore, inhibition of p53-MDM2 interaction leads to reactivating p53 activity. Alkaloid compounds generally have potential anticancer effect. Alkaloid compound from Mitragyna speciosa have the potential for anticancer. Methods: The method used is molecular docking with AutoDockTools 1.5.6 program. Predict the properties of physicochemical, pharmacokinetic, and toxicity prediction tests (ADMET) using pkCSM. Results: The results showed that speciophylline, corynoxine A, and corynoxine B have the best values in free binding energy (ΔG) for estrogen receptor (ERα) alpha receptor. Meanwhile, mitraphylline, mitrafoline, and corynoxine B have the best values for protein P53. Predict ADMET using the pkCSM, the alkaloid compound has strong lipophilicity and good permeability so it predicts the ability to penetrate intestinal cell membranes and the skin membrane. Spesiofilin, mitraphylline, and mitrafolin are not expected hepatotoxic. Conclusion: Speciophylline and mitraphylline have potential as anticancer drugs through the inhibitory of estrogen receptor alpha and MDM2 reseptor.

}, keywords = {ADMET, Alkaloid, Breast cancer, Docking, Mitragyna speciosa}, doi = {10.5530/pj.2022.14.188}, author = {Puja Adi Priatna and Rizki Rahmadi Pratama and Retno Widyowati and Sukardiman} }